BamSEC and AlphaSense Join Forces
Learn More

CRISPR Therapeutics AG

NASDAQ: CRSP    
Share price (12/20/24): $40.72    
Market cap (12/20/24): $3.476 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 16 pages Indemnification Agreement
12/34/56
EX-10.2
from 10-Q 18 pages Employment Agreement
12/34/56
EX-10
from 8-K 17 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 26 pages Investment Agreement
12/34/56
EX-10.1
from 8-K 7 pages Amendment No. 1 to the Amended and Restated Joint Development and Commercialization Agreement
12/34/56
EX-10
from 8-K 43 pages [***] Certain Portions of This Exhibit Have Been Omitted Because They Are Not Material and the Registrant Customarily and Actually Treats That Information as Private or Confidential. Certain Exhibits and Schedules to These Agreements Have Been Omitted Pursuant to Item 601 of Regulation S-K. Non-Exclusive License Agreement Between Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG March 23, 2023 Non-Exclusive License Agreement
12/34/56
EX-10
from 8-K 17 pages Employment Agreement
12/34/56
EX-10.2
from 10-Q 2 pages Lease Commencement Date Agreement
12/34/56
EX-10.1
from 10-Q 17 pages Employment Agreement
12/34/56
EX-10.37
from 10-K 5 pages 105 W. First Street Owner, L.L.C. C/O Breakthrough Spaces, L.L.C. Tishman Speyer
12/34/56
EX-10.32
from 10-K 3 pages Pfizer Inc
12/34/56
EX-10.1
from 8-K 16 pages Employment Agreement
12/34/56
EX-10.2
from 10-Q 2 pages [***] Certain Portions of This Exhibit Have Been Omitted Because They Are Not Material and the Registrant Customarily and Actually Treats That Information as Private or Confidential
12/34/56
EX-10.1
from 10-Q 5 pages 33 New York Avenue Framingham, Ma Second Amendment to Lease CRISPR Therapeutics, Inc
12/34/56
EX-10.4
from 10-Q 69 pages Amended and Restated Joint Development and Commercialization Agreement Between Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals (Europe) Limited and CRISPR Therapeutics AG Crispr Therapeutics Limited Crispr Therapeutics, Inc. Tracr Hematology Ltd
12/34/56
EX-10.3
from 10-Q 4 pages Amendment No. 1 to the Strategic Collaboration and License Agreement
12/34/56
EX-10.2
from 10-Q 6 pages 33 New York Avenue Framingham, Massachusetts 01701 (The “Building”) First Amendment
12/34/56
EX-10.1
from 10-Q 97 pages 33 New York Avenue Framingham, Massachusetts 01701 Lease Summary Sheet
12/34/56
EX-10.1
from 10-Q 114 pages Lease 105 W First Street Owner, L.L.C., a Delaware Limited Liability Company Landlord and CRISPR Therapeutics, Inc., a Delaware Corporation Tenant for Premises at the 105 by Breakthrough 105 West First Street Boston, Massachusetts July 24, 2020
12/34/56
EX-10.32
from 10-K 59 pages [***] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Assignment of Sublease and Sub-Sublease
12/34/56